Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus
- 1 April 1995
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 14 (4) , 318-329
- https://doi.org/10.1007/bf02116525
Abstract
Sixteen freshly isolated varicella-zoster virus (VZV) strains were evaluated in vitro, in parallel with two reference strains expressing a functional thymidine kinase (TK+) (Oka and YS) and two thymidine kinase-deficient mutants (TK−) (07–1 and YS-R), for their susceptibility to a broad range of antiviral compounds. The following compounds were included: acyclovir (ACV), brivudine (BVDU), sorivudine (BVaraU), other BVDU congeners such as BTDU, CTDU, CVDC and CVDU, ganciclovir (GCV), FIAC, araT, araA, araC, foscarnet (PFA), phosphonoacetic acid (PAA), the acyclic nucleoside phosphonates HPMPC, cHPMPC, HPMPA, cHPMPA, HPMPc3A, PMEA and PMEDAP, the N7-isomeric acyclic nucleoside analogue N7 AP, penciclovir (PCV), compounds 882C87 and H2G and two oxetanocin derivatives OXT-A and OXT-G. Fourteen of the 16 clinical isolates displayed the following order of decreasing selectivity against VZV: BVaraU > BVDU > CVDU ∼ CVDC > H2G > N7AP } CTDU ∼ BTDU ∼ OXT-G ∼ 882C87 > ACV > FIAC ∼ araT > HPMPC ∼ cHPMPC ∼ HPMPA ∼ HPMPc3A ∼ cHPMPA > PCV ∼ GCV ∼ OXT-A > PMEDAP ∼ PMEA > PFA ∼ PAA ∼ araA > araC. Two VZV strains (isolated from the cerebrospinal fluid of an AIDS patient) that were shown to have a truncated TK were clearly resistant to all the compounds that need the viral TK for their phosphorylation, while sensitivity to the acyclic nucleoside phosphonates, PFA, PAA, OXT-A and araA, remained unchanged. A slight (5- and 10-fold) increase was noted in the 50 % inhibitory concentration of N7AP and OXT-G, respectively, for the TK− VZV strains as compared to the TK+ VZV strains. Ganciclovir and FIAC also showed a marked decrease in their activity against these two strains, but this was not as pronounced as for the other viral TK-dependent drugs. From our results, it appears that although acyclic nucleoside phosphonates may not have as favourable a therapeutic index as drugs requiring the viral TK, they should be considered for the treatment of TK− VZV life-threatening infections that are resistant to the viral TK-dependent drugsThis publication has 55 references indexed in Scilit:
- Disseminated Herpes Zoster in the Immunocompromised Host: A Comparative Trial of Acyclovir and VidarabineThe Journal of Infectious Diseases, 1992
- Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeysAntiviral Research, 1991
- (±)-(1α,2β,3α)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(±)-BHCG or SQ 33 054]: A potent and selective inhibitor of herpesvirusesAntiviral Research, 1990
- Acyclovir Prevents Dissemination of Varicella in Immunocompromised ChildrenThe Journal of Infectious Diseases, 1988
- In vitro activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-adenine against newly isolated clinical varicella-zoster viras strainsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Treatment of Varicella–Zoster Virus Infection in Severely Immunocompromised PatientsNew England Journal of Medicine, 1986
- Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella-zoster virus strains.The Tohoku Journal of Experimental Medicine, 1986
- Influence of various experimental conditions on the inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on varicella-zoster virus replication in cell culture.The Tohoku Journal of Experimental Medicine, 1984
- Vidrabine therapy of varicella in immunosuppressed patientsThe Journal of Pediatrics, 1982
- Treatment of Varicella-Zoster Virus Infections with Adenine ArabinosideThe Journal of Infectious Diseases, 1975